| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 42 | 2024 | 1757 | 7.500 |
Why?
|
| Image-Guided Biopsy | 15 | 2024 | 79 | 3.780 |
Why?
|
| Kidney Neoplasms | 14 | 2021 | 526 | 3.030 |
Why?
|
| Prostate | 18 | 2023 | 410 | 2.880 |
Why?
|
| Cryosurgery | 7 | 2024 | 59 | 2.430 |
Why?
|
| Ablation Techniques | 5 | 2024 | 38 | 2.270 |
Why?
|
| Carcinoma, Renal Cell | 7 | 2021 | 333 | 2.210 |
Why?
|
| Magnetic Resonance Imaging | 21 | 2024 | 3500 | 2.190 |
Why?
|
| Nephrectomy | 5 | 2016 | 295 | 1.390 |
Why?
|
| Prostatectomy | 7 | 2022 | 476 | 1.160 |
Why?
|
| Male | 57 | 2024 | 43249 | 1.110 |
Why?
|
| Ultrasonography | 4 | 2023 | 723 | 0.990 |
Why?
|
| Urology | 3 | 2018 | 124 | 0.960 |
Why?
|
| Humans | 66 | 2024 | 91073 | 0.830 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 2 | 2024 | 47 | 0.820 |
Why?
|
| Valproic Acid | 2 | 2012 | 24 | 0.770 |
Why?
|
| Retrospective Studies | 20 | 2022 | 9399 | 0.720 |
Why?
|
| Radiotherapy | 2 | 2019 | 321 | 0.690 |
Why?
|
| Neoplasm Grading | 9 | 2020 | 376 | 0.680 |
Why?
|
| Salvage Therapy | 2 | 2022 | 233 | 0.630 |
Why?
|
| Biopsy | 6 | 2024 | 1196 | 0.620 |
Why?
|
| Prostate-Specific Antigen | 8 | 2024 | 343 | 0.620 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 99 | 0.620 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 1374 | 0.590 |
Why?
|
| Brachytherapy | 1 | 2018 | 121 | 0.580 |
Why?
|
| Middle Aged | 30 | 2024 | 26555 | 0.560 |
Why?
|
| Ascites | 1 | 2016 | 56 | 0.540 |
Why?
|
| Pharmaceutical Preparations | 1 | 2017 | 91 | 0.530 |
Why?
|
| Creatine Kinase | 1 | 2016 | 53 | 0.520 |
Why?
|
| Immunotherapy | 2 | 2014 | 702 | 0.510 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 608 | 0.510 |
Why?
|
| Ultrasonography, Interventional | 5 | 2020 | 126 | 0.510 |
Why?
|
| Aged | 21 | 2024 | 19574 | 0.510 |
Why?
|
| Peritoneal Neoplasms | 1 | 2016 | 182 | 0.490 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 432 | 0.480 |
Why?
|
| Remote Consultation | 1 | 2014 | 16 | 0.470 |
Why?
|
| Photography | 1 | 2014 | 38 | 0.470 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 4 | 2019 | 27 | 0.470 |
Why?
|
| Cell Phone | 1 | 2014 | 38 | 0.460 |
Why?
|
| Decision Making | 2 | 2011 | 675 | 0.460 |
Why?
|
| Frozen Sections | 1 | 2014 | 49 | 0.450 |
Why?
|
| Medical Oncology | 1 | 2017 | 390 | 0.430 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2012 | 1 | 0.420 |
Why?
|
| Nitrofurantoin | 1 | 2012 | 1 | 0.420 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2012 | 32 | 0.410 |
Why?
|
| Urethral Neoplasms | 1 | 2012 | 10 | 0.400 |
Why?
|
| Urethral Diseases | 1 | 2012 | 15 | 0.400 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 68 | 0.400 |
Why?
|
| Watchful Waiting | 2 | 2021 | 68 | 0.400 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2012 | 70 | 0.400 |
Why?
|
| Urinary Tract Infections | 1 | 2012 | 75 | 0.390 |
Why?
|
| Self Care | 2 | 2014 | 166 | 0.390 |
Why?
|
| Diverticulum | 1 | 2012 | 45 | 0.390 |
Why?
|
| Neuroendocrine Cells | 1 | 2010 | 4 | 0.360 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 2682 | 0.350 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 354 | 0.350 |
Why?
|
| Physicians | 1 | 2017 | 691 | 0.340 |
Why?
|
| Adenoma | 1 | 2012 | 251 | 0.340 |
Why?
|
| Surgeons | 1 | 2014 | 253 | 0.340 |
Why?
|
| Embolization, Therapeutic | 1 | 2012 | 267 | 0.330 |
Why?
|
| Cryotherapy | 1 | 2009 | 30 | 0.330 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 323 | 0.330 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 538 | 0.320 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 3 | 2020 | 35 | 0.320 |
Why?
|
| Urologic Neoplasms | 1 | 2009 | 74 | 0.310 |
Why?
|
| Population Surveillance | 2 | 2020 | 209 | 0.290 |
Why?
|
| Prospective Studies | 5 | 2024 | 4367 | 0.280 |
Why?
|
| Treatment Outcome | 9 | 2022 | 8436 | 0.270 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 982 | 0.270 |
Why?
|
| Logistic Models | 3 | 2016 | 1216 | 0.250 |
Why?
|
| Prognosis | 5 | 2017 | 3825 | 0.250 |
Why?
|
| Medicare | 2 | 2020 | 432 | 0.250 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 464 | 0.250 |
Why?
|
| Adult | 15 | 2018 | 27147 | 0.250 |
Why?
|
| Databases, Factual | 3 | 2017 | 882 | 0.230 |
Why?
|
| Quality of Life | 3 | 2022 | 1699 | 0.230 |
Why?
|
| Postoperative Complications | 2 | 2016 | 2348 | 0.230 |
Why?
|
| Cell Differentiation | 1 | 2010 | 1564 | 0.220 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 1183 | 0.220 |
Why?
|
| Delphi Technique | 2 | 2021 | 104 | 0.220 |
Why?
|
| Female | 15 | 2021 | 47186 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2017 | 367 | 0.220 |
Why?
|
| Yoga | 1 | 2022 | 6 | 0.200 |
Why?
|
| Meditation | 1 | 2022 | 5 | 0.200 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2022 | 6 | 0.200 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 1144 | 0.190 |
Why?
|
| United States | 6 | 2020 | 7188 | 0.190 |
Why?
|
| Biopsy, Large-Core Needle | 2 | 2018 | 15 | 0.190 |
Why?
|
| Mobile Applications | 1 | 2022 | 73 | 0.180 |
Why?
|
| Tobacco Smoking | 1 | 2021 | 30 | 0.180 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 42 | 0.180 |
Why?
|
| Asthma | 1 | 2009 | 994 | 0.180 |
Why?
|
| Survival Rate | 2 | 2016 | 1898 | 0.180 |
Why?
|
| Urologists | 2 | 2018 | 34 | 0.170 |
Why?
|
| Kallikreins | 1 | 2020 | 46 | 0.170 |
Why?
|
| Urinary Incontinence | 1 | 2022 | 216 | 0.170 |
Why?
|
| Mice, Nude | 2 | 2012 | 821 | 0.170 |
Why?
|
| Hypogonadism | 1 | 2019 | 40 | 0.160 |
Why?
|
| Fluorine Radioisotopes | 1 | 2019 | 25 | 0.160 |
Why?
|
| Laser Therapy | 1 | 2021 | 149 | 0.160 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 116 | 0.160 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 439 | 0.160 |
Why?
|
| Survival Analysis | 3 | 2017 | 1500 | 0.160 |
Why?
|
| Terminology as Topic | 1 | 2020 | 224 | 0.150 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2018 | 300 | 0.150 |
Why?
|
| Organ Sparing Treatments | 1 | 2018 | 47 | 0.150 |
Why?
|
| Creatinine | 2 | 2016 | 295 | 0.150 |
Why?
|
| Neoplasms | 1 | 2014 | 3053 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2019 | 143 | 0.150 |
Why?
|
| Testosterone | 1 | 2019 | 272 | 0.150 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 198 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 2 | 2016 | 280 | 0.150 |
Why?
|
| Racism | 1 | 2020 | 95 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 1713 | 0.150 |
Why?
|
| Tumor Burden | 1 | 2019 | 316 | 0.150 |
Why?
|
| Patient Participation | 2 | 2011 | 227 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 341 | 0.140 |
Why?
|
| Paraganglioma | 1 | 2017 | 15 | 0.140 |
Why?
|
| Drug Industry | 1 | 2017 | 54 | 0.140 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 64 | 0.140 |
Why?
|
| Cell Line, Tumor | 3 | 2012 | 2615 | 0.140 |
Why?
|
| Laparoscopy | 3 | 2014 | 783 | 0.140 |
Why?
|
| Cystectomy | 1 | 2017 | 110 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 854 | 0.140 |
Why?
|
| Disclosure | 1 | 2017 | 109 | 0.140 |
Why?
|
| Platelet Count | 1 | 2016 | 93 | 0.140 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 99 | 0.140 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 3716 | 0.130 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 2022 | 0.130 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 222 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 85 | 0.130 |
Why?
|
| Animals | 6 | 2014 | 27783 | 0.130 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2018 | 333 | 0.120 |
Why?
|
| Genital Diseases, Male | 1 | 2014 | 9 | 0.120 |
Why?
|
| Vasectomy | 1 | 2014 | 4 | 0.120 |
Why?
|
| Linear Models | 1 | 2016 | 426 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2016 | 235 | 0.120 |
Why?
|
| Medicaid | 1 | 2017 | 244 | 0.120 |
Why?
|
| Kidney | 2 | 2016 | 1153 | 0.120 |
Why?
|
| Text Messaging | 1 | 2014 | 31 | 0.110 |
Why?
|
| Hematuria | 1 | 2014 | 50 | 0.110 |
Why?
|
| Color | 1 | 2014 | 85 | 0.110 |
Why?
|
| Intraoperative Period | 1 | 2014 | 91 | 0.110 |
Why?
|
| Urine | 1 | 2014 | 94 | 0.110 |
Why?
|
| Pathology, Clinical | 1 | 2014 | 34 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2016 | 897 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2017 | 554 | 0.110 |
Why?
|
| Hematoma | 1 | 2014 | 108 | 0.110 |
Why?
|
| Biomarkers | 2 | 2021 | 1814 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2014 | 103 | 0.110 |
Why?
|
| Choice Behavior | 1 | 2014 | 162 | 0.100 |
Why?
|
| Immunity | 1 | 2014 | 141 | 0.100 |
Why?
|
| ROC Curve | 2 | 2016 | 785 | 0.100 |
Why?
|
| Incidence | 1 | 2016 | 1599 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2012 | 103 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 342 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 652 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2020 | 0.090 |
Why?
|
| Men | 1 | 2011 | 10 | 0.090 |
Why?
|
| Chromogranin A | 1 | 2010 | 8 | 0.090 |
Why?
|
| Synaptophysin | 1 | 2010 | 11 | 0.090 |
Why?
|
| Models, Genetic | 1 | 2016 | 962 | 0.090 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2010 | 15 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 2375 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 327 | 0.090 |
Why?
|
| Staining and Labeling | 1 | 2010 | 173 | 0.090 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2010 | 42 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 303 | 0.080 |
Why?
|
| Ultrasonography, Doppler | 1 | 2009 | 85 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 1066 | 0.080 |
Why?
|
| Patient Selection | 3 | 2018 | 685 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 492 | 0.080 |
Why?
|
| Mice | 3 | 2012 | 11993 | 0.080 |
Why?
|
| Consensus | 2 | 2021 | 374 | 0.080 |
Why?
|
| India | 1 | 2009 | 126 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 2009 | 115 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 134 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 303 | 0.080 |
Why?
|
| Developing Countries | 1 | 2009 | 81 | 0.080 |
Why?
|
| Personal Autonomy | 1 | 2009 | 116 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 1750 | 0.070 |
Why?
|
| Neoplasms, Experimental | 1 | 2009 | 270 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2009 | 590 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2009 | 402 | 0.070 |
Why?
|
| SEER Program | 2 | 2017 | 202 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2018 | 338 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 2416 | 0.070 |
Why?
|
| Mesothelioma | 1 | 2009 | 326 | 0.070 |
Why?
|
| Age Factors | 1 | 2011 | 1876 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 6847 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2012 | 1695 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2711 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2016 | 3442 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 613 | 0.060 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 500 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2347 | 0.060 |
Why?
|
| Mutation | 1 | 2016 | 4203 | 0.060 |
Why?
|
| Risk Factors | 2 | 2017 | 5608 | 0.060 |
Why?
|
| Demography | 2 | 2017 | 184 | 0.060 |
Why?
|
| Early Detection of Cancer | 2 | 2018 | 427 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 1753 | 0.050 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2020 | 60 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 2380 | 0.040 |
Why?
|
| Urogenital Neoplasms | 1 | 2017 | 24 | 0.030 |
Why?
|
| Nephrons | 1 | 2016 | 17 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 234 | 0.030 |
Why?
|
| Professional Practice Location | 1 | 2016 | 6 | 0.030 |
Why?
|
| Nomograms | 1 | 2016 | 32 | 0.030 |
Why?
|
| Operative Time | 1 | 2016 | 150 | 0.030 |
Why?
|
| Adolescent | 1 | 2009 | 9411 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 116 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 303 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 2904 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 308 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 336 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 388 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 863 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 758 | 0.030 |
Why?
|
| Contrast Media | 1 | 2018 | 1085 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 185 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 852 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 1169 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2009 | 123 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 238 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 326 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1559 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 1102 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 607 | 0.020 |
Why?
|